文献速递复苏、休克与脓毒症心脑血管急症

普罗帕酮胺用于可电击心律心脏骤停:复苏结局联盟(ROC)研究

Procainamide for shockable rhythm cardiac arrest in the Resuscitation Outcome Consortium.
PubMed 文献 · Am J Emerg Med · 2022-02-24
一句话结论在可电击心律的院外心脏骤停中,普罗帕酮胺与胺碘酮或利多卡因在院前ROSC、急诊ROSC及出院生存率上无显著差异,其在OHCA中的作用仍不明确。

本研究基于复苏结局联盟(ROC)Epistry 3登记数据,纳入初始为可电击心律且接受抗心律失常药物的院外心脏骤停(OHCA)患者3087例,按用药分为普罗帕酮胺组(51例)、胺碘酮组(1776例)和利多卡因组(1418例)。采用1:1倾向性评分匹配比较普罗帕酮胺与胺碘酮、利多卡因,并辅以多因素logistic回归。倾向性评分分析显示,与普罗帕酮胺相比,胺碘酮的院前ROSC(OR 0.7,95%CI 0.3-1.8)、急诊ROSC(OR 0.6,95%CI 0.3-1.3)及出院生存率(OR 1.0,95%CI 0.3-3.1)均无显著差异;利多卡因的院前ROSC(OR 0.9,95%CI 0.4-2.2)、急诊ROSC(OR 1.2,95%CI 0.5-2.7)及出院生存率(OR 1.4,95%CI 0.5-4.0)亦无显著差异。但多因素回归显示,胺碘酮的院前ROSC低于普罗帕酮胺(aOR 0.3,95%CI 0.1-0.6)。作者认为普罗帕酮胺在OHCA中的作用仍不明确。

要点

  • 在初始可电击心律的OHCA患者中,倾向性评分匹配后,胺碘酮与普罗帕酮胺的院前ROSC(OR 0.7,95%CI 0.3-1.8)、急诊ROSC(OR 0.6,95%CI 0.3-1.3)及出院生存率(OR 1.0,95%CI 0.3-3.1)均无显著差异。
  • 利多卡因与普罗帕酮胺的院前ROSC(OR 0.9,95%CI 0.4-2.2)、急诊ROSC(OR 1.2,95%CI 0.5-2.7)及出院生存率(OR 1.4,95%CI 0.5-4.0)亦无显著差异。
  • 多因素回归分析中,胺碘酮的院前ROSC低于普罗帕酮胺(aOR 0.3,95%CI 0.1-0.6)。
  • 接受普罗帕酮胺的患者仅51例,而胺碘酮组1776例、利多卡因组1418例,普罗帕酮胺组样本量很小。
  • 作者结论:普罗帕酮胺在OHCA中的作用仍不明确。

适用人群与场景

  • 复苏结局联盟(ROC)Epistry 3登记中所有初始为可电击心律且接受了抗心律失常药物的院外心脏骤停(OHCA)患者。

研究设计与关键结果

  • 研究类型:基于ROC Epistry 3登记数据的分析;纳入3087例初始可电击心律且接受抗心律失常药物的OHCA患者。
  • 分组:普罗帕酮胺组51例(仅接受普罗帕酮胺),胺碘酮组1776例,利多卡因组1418例。
  • 方法:利用可能混杂因素定义倾向性评分,采用1:1倾向性评分匹配比较普罗帕酮胺与胺碘酮、利多卡因,匹配数据用logistic回归分析;另用多因素logistic回归评估抗心律失常药物与结局的关联。
  • 主要终点(倾向性评分分析,与普罗帕酮胺相比):胺碘酮院前ROSC OR 0.7(95%CI 0.3-1.8),急诊ROSC OR 0.6(95%CI 0.3-1.3),出院生存率 OR 1.0(95%CI 0.3-3.1);利多卡因院前ROSC OR 0.9(95%CI 0.4-2.2),急诊ROSC OR 1.2(95%CI 0.5-2.7),出院生存率 OR 1.4(95%CI 0.5-4.0)。
  • 多因素回归:胺碘酮院前ROSC低于普罗帕酮胺(aOR 0.3,95%CI 0.1-0.6)。

证据类型、等级与局限

  • 证据类型:基于注册登记数据的观察性分析(ROC Epistry 3)。
  • 局限:普罗帕酮胺组仅51例,样本量很小;作者结论指出普罗帕酮胺在OHCA中的作用仍不明确。

对床旁实践的改变

  • 作者认为普罗帕酮胺在OHCA中的作用仍不明确。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: With recent negative studies of amiodarone and lidocaine for cardiac arrest, research into other antiarrhythmics is warranted. Literature on procainamide in cardiac arrest is limited. We evaluated procainamide for out-of-hospital cardiac arrests (OHCA) from the Resuscitation Outcomes Consortium (ROC).

METHODS: We included all ROC Epistry 3 OHCAs with an initial shockable rhythm that received an antiarrhythmic. We stratified cases by antiarrhythmic: procainamide, amiodarone, or lidocaine. The outcomes were prehospital return of spontaneous circulation (ROSC), ROSC in the ED, and survival to hospital discharge. We defined propensity scores based on possible confounders utilizing 1:1 propensity score matching to compare procainamide to amiodarone and lidocaine. We analyzed the matched data using logistic regression. We also used multivariable logistic regression to evaluate the association between antiarrhythmic and outcomes.

RESULTS: 3087 subjects met inclusion criteria; 51 patients received only procainamide, 1776 received amiodarone, and 1418 received lidocaine. On propensity score analysis and compared to procainamide, amiodarone had similar prehospital ROSC (OR 0.7, 95% CI 0.3-1.8), ED ROSC (OR 0.6, 95% CI 0.3-1.3), and survival (OR 1.0, 95% CI 0.3-3.1). Lidocaine also had a similar prehospital ROSC (OR 0.9, 95% CI 0.4-2.2), ED ROSC (OR 1.2, 95% CI 0.5-2.7), and survival (OR 1.4, 95% CI 0.5-4.0). However, using multivariable regression, amiodarone had lower prehospital ROSC than procainamide (aOR 0.3, 95% CI 0.1-0.6).

CONCLUSIONS: While associated with increased prehospital ROSC when compared with amiodarone using multivariable regression, procainamide otherwise had similar prehospital ROSC, ED ROSC, and survival. The role of procainamide in OHCA remains unclear.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Huebinger R, Harvin JA, Chan HK, et al. Procainamide for shockable rhythm cardiac arrest in the Resuscitation Outcome Consortium. Am J Emerg Med. 2022. PMID: 35325787. doi:10.1016/j.ajem.2022.02.031

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。